HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup AnalysisPaul G. Richardson, Joan Bladé Creixenti, Omar Nadeem et al.|Blood|2020Cited by 11
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup AnalysisPaula Rodríguez‐Otero, Paul G. Richardson, María‐Victoria Mateos et al.|Blood|2020Cited by 2
MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup AnalysisPaul G. Richardson, Joan Bladé, María‐Victoria Mateos et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1
Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup AnalysisPaul G. Richardson, Joan Bladé, Johan Harmenberg et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 0